Bronchiolitis Obliterans Clinical Trial
Official title:
Prospective Study for Transplant Optimization Using Functional Imaging (TROFI)
Verified date | October 2017 |
Source | FLUIDDA nv |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to detect BOS in an early stage by using the outcome parameters generated by Functional Respiratory Imaging (FRI). Robust and automated segmentation algorithms will be developed for these parameters, focusing on quantitative computed tomography (CT) image analyses to provide the physician a more sensitive diagnostics tool. The evolution of rejection over time will be monitored using non-rigid image registration methods.
Status | Terminated |
Enrollment | 10 |
Est. completion date | December 15, 2017 |
Est. primary completion date | December 15, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female patient = 18 years old - Written informed consent obtained - Patients who are planned to receive a lung transplant in the near future - Female patient of childbearing potential who confirm that a contraception method was used at least 14 days before screening visit and will continue to use a contraception method during the study - The patient must be able to perform the lung monitoring at home Exclusion Criteria: - Pregnant or lactating female - Known history of or active airways or anastomotic complications requiring intervention such as stenting or dilation |
Country | Name | City | State |
---|---|---|---|
Belgium | Antwerp University Hospital | Edegem | Antwerp |
Lead Sponsor | Collaborator |
---|---|
FLUIDDA nv |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Airway Volume (iVaw) using FRI | Exploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7. | 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplant | |
Primary | Change in Airway Resistance (iRaw) using FRI | Exploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7. Airway resistance is defined as the pressure drop over the airways divided by the airflow. | 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplant | |
Primary | Change in Specific Airway Volume (siVaw) using FRI | Exploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7. | 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplant | |
Primary | Change in Specific Airway Resistance (siRaw) using FRI | Exploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7. | 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplant | |
Primary | Change in Lobe Volumes (iVlobes) using FRI | Exploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7. | 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplant | |
Primary | Change in Air trapping using FRI | Exploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7. Air trapping is defined as the regions in the lung with a gray value on the CT-scan image smaller than -850 HU at functional residual capacity. | 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplant | |
Primary | Change in Internal Lobar Airflow Distribution using FRI | Exploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7. Airflow distribution is defined in as the percentage of air going to every lobe when inhaling from FRC to TLC and is calculated for every lobe as: IALDlobe [%] = 100 (VTLC_lobe - VFRC_lobe) / (VTLC_lungs - VFRC_lungs). | 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplant | |
Primary | Change in Low Attenuation or Emphysema Score using FRI | Exploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7. | 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplant | |
Primary | Change in Blood Vessel Density or Fibrosis Score using FRI | Exploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7. | 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplant | |
Primary | Change in Airway Wall Thickness using FRI | Exploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7. | 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplant |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03603899 -
Hp129 Xenon Imaging and BOS in Lung Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT04098445 -
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
|
||
Completed |
NCT02441413 -
Transplant Optimization Using Functional Imaging (TROFI)
|
N/A | |
Recruiting |
NCT02543073 -
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
|
Phase 1/Phase 2 | |
Terminated |
NCT01432080 -
Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant
|
Phase 2 | |
Recruiting |
NCT00163696 -
Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease
|
N/A | |
Completed |
NCT00029328 -
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
|
Phase 1/Phase 2 | |
Terminated |
NCT01163786 -
A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD
|
Phase 2 | |
Recruiting |
NCT02627833 -
Lung Function, LCI, Bronchial Inflammation and Epigenetics of Patients With BO
|
N/A | |
Completed |
NCT01211509 -
Montelukast in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
Completed |
NCT01212406 -
Vitamin D in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
Completed |
NCT00701922 -
Surveillance Study of Viral Infections Following Lung Transplantation
|
N/A | |
Completed |
NCT00141726 -
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT05922761 -
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
|
Phase 2 | |
Recruiting |
NCT05881538 -
High Intensity Intervallic Training in Children With Bronchiolitis Obliterans
|
N/A | |
Terminated |
NCT04655508 -
Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation
|
Phase 3 | |
Withdrawn |
NCT02109237 -
Sleep Disorders in Bronchiolitis Obliterans Syndrome 2&3
|
N/A | |
Completed |
NCT01327248 -
Clinical Status and Bronchial Inflammation in Patients With Bronchiolitis Obliterans
|
N/A | |
Recruiting |
NCT05932316 -
Evaluating Bronchodilator Response in Patients With Bronchiectasis
|
N/A | |
Active, not recruiting |
NCT03656926 -
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)
|
Phase 3 |